或著誰有住美國的 能幫忙我買回來??? 請與我聯絡
- naekuoLv 71 decade agoFavorite Answer
1. 不2. 美國糧食與藥物管理局(FDA)對該產品的認證&認同之後,然後藥物將上市。Setting aside the Guidant drama for a moment, J&J stands to benefit from as many as seven drug candidates that are up for market approval in the not-too-distant future. In addition, J&J has a cash hoard of around $15.2 billion, and it has the potential to generate $10 billion more this year, Weinstein believes. Needless to say, the health care giant has the resources to make multiple acquisitions this year, should it choose to go that route. Among the products Weinstein expects to be up for regulatory clearance by next year are the painkiller Ionsys, Dapoxetine for premature ejaculation, HIV drugs TMC-114 and TMC-125, the schizophrenia drug Paliperidone ER and Yondelis for a type of cancer called soft-tissue sarcoma. Weinstein adds that even without Guidant, J&J is worth owning, particularly in light of its cash position. On top of that, J&J could reach 10% earnings growth in each of the next three years, Weinstein wrote in a research report.